Aft Pharmaceuticals Ltd (AFP) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Aft Pharmaceuticals Ltd stock A$1.62, price A$3.55, that is 54.4% below the price, quality 53 out of 100. Rating: strongly overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range A$2.13 – A$4.73 · fair‑value band A$0.7700 – A$3.09 · the A$3.55 price screens above the A$1.62 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Aft Pharmaceuticals in your weekly email
Every Wednesday you see whether Aft Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally.
Show moreShow less
The company offers proprietary and in-licensed products, including patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, natural health, pain management, skin care, sleeping aids, supplements, and other products.
It has a research and development collaboration with Hyloris Pharmaceuticals SA for the development of the Maxigesic IV product. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.
Stock analysis
Aft Pharmaceuticals Ltd (AFP) currently trades at A$3.55, while our model-based Fair Value estimate is A$1.62, 54% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of A$2.81 per share, and 1 of the 17 models we run sit above the A$3.55 price.
Bear case: the Dividend Discount group reads lowest at A$0.2000, and 16 of the 17 models stay below the price. Data coverage for this calculation is high.
Scenario range: A$0.7700 (bear) to A$3.09 (bull), the price of A$3.55 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Aft Pharmaceuticals Ltd reported revenue of 257M NZD in FY2026 versus 130M NZD in FY2022, a compound +18.5%/yr. Reported net income was 14.8M NZD in FY2026, compounding −7.0%/yr from FY2022.
Key figures
Market cap A$372M (≈ $257M) Micro · P/E ratio 29.6 · P/S ratio 1.80 · EPS (TTM) A$0.1200 · Dividend yield 0.7% · Net margin 5.8% · Return on equity 13.7% · Return on assets (EBIT) 12.0% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 32% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −54%, AFP screens richer than that median.
Fair Value models
BearA$0.7700Fair Value A$1.62BullA$3.09
Price A$3.55 · Downside -54.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (A$0.0580 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+24.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.8%
Start year 2021 (pandemic). Over 10 years: +14.9% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.3%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+3.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.2%
Dividend (yield on the price)0.7%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 10%
Compare Aft Pharmaceuticals Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside−54.4% · Below median
Profitability
Return on equity (12 months)13.7% · Above median
Return on assets6.8% · Above median
Net margin (12 months)5.8% · Below median
Operating margin (12 months)14.1% · Above median
Growth and dividend
Revenue growth (quarter YoY)15.2% · Above median
Dividend yield (12 months)0.7% · Below median
Balance sheet
Debt / equity0.35× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)29.6× · Pricier than median
P/B4.13× · Priciest 25%
P/S (12 months)1.80× · Cheaper than median
EV/EBITDA19.6× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)76· sector 25
PAST (return on equity)55· sector 29
HEALTH (low debt)82· sector 96
DIVIDEND (yield)14· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Aft Pharmaceuticals Ltd (AFP) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of A$1.62 versus a price of A$3.55, about 54% lower (overvalued).
What is the fair value of AFP?
Our model-based fair value for Aft Pharmaceuticals Ltd is A$1.62 (as of Nov 6, 2026), built from audited fundamentals. The current price: A$3.55.
What is the quality score of AFP?
Aft Pharmaceuticals Ltd has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aft Pharmaceuticals Ltd (AFP)?
Our model-based price target is the fair value of A$1.62 (as of Nov 6, 2026) from 17 valuation models. Cautious scenario A$0.7700, optimistic scenario A$3.09. It is a calculation from audited fundamentals, not an analyst target.
What is the Aft Pharmaceuticals Ltd stock forecast for 2026?
Our models put fair value at A$1.62, about 54% lower versus a price of A$3.55 (overvalued). Cautious scenario A$0.7700, optimistic scenario A$3.09. The calculation is refreshed regularly with new filings.
What is the revenue of Aft Pharmaceuticals Ltd (AFP)?
Aft Pharmaceuticals Ltd reported trailing-twelve-month revenue of about 255M NZD (latest available figure, as of Nov 6, 2026).
Does Aft Pharmaceuticals Ltd pay a dividend?
Aft Pharmaceuticals Ltd currently shows a dividend yield of 0.70% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Aft Pharmaceuticals Ltd (AFP) and when is the ex-dividend date?
Aft Pharmaceuticals Ltd pays a dividend of A$0.025 per share a year, a dividend yield of 0.7%. The last ex-dividend date was Jun 18, 2026. The payout ratio is 12.8% of earnings. Our assessment: Token dividend. At a yield of 0.7% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.7% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Aft Pharmaceuticals Ltd (AFP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aft Pharmaceuticals Ltd it is A$1.62 per share (as of Nov 6, 2026), against a price of A$3.55. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Aft Pharmaceuticals Ltd stock overvalued or undervalued in 2026?
As of Nov 6, 2026, AFP trades above its calculated fair value: price A$3.55, fair value A$1.62, a gap of about −54% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AFP?
No. The price is what the market pays today (A$3.55); the fair value is what the company's own numbers justify (A$1.62). For Aft Pharmaceuticals Ltd the two are A$1.93 per share apart. That gap is exactly why we show both numbers side by side.
How much is Aft Pharmaceuticals Ltd worth?
The market values Aft Pharmaceuticals Ltd at about A$372M (market capitalisation, as of Nov 6, 2026). Per share that is A$3.55; our models calculate a fair value of A$1.62 per share.
What do the bullish and bearish scenarios say about AFP?
Our models span a range for Aft Pharmaceuticals Ltd: cautious scenario A$0.7700, base A$1.62, optimistic A$3.09 per share (as of Nov 6, 2026, price A$3.55). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of AFP?
Aft Pharmaceuticals Ltd trades at a price-to-earnings ratio of 29.6 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of A$1.62 is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2020 to 2026), reported earnings: 23.2. Other multiples: P/B 4.1, P/S 1.8, EV/EBITDA 19.6.
How solid is the balance sheet of Aft Pharmaceuticals Ltd (AFP)?
Balance-sheet figures for Aft Pharmaceuticals Ltd (as of Nov 6, 2026): return on equity 13.7%, debt of 0.35 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is AFP from its 52-week high?
Aft Pharmaceuticals Ltd trades at A$3.55, about 13% below its 52-week high of A$4.10 and 32% above the low of A$2.70 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of A$1.62 is for.
Which stocks are comparable to Aft Pharmaceuticals Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aft Pharmaceuticals Ltd stock attractive at the current price?
The data as of Nov 6, 2026: price A$3.55, calculated fair value A$1.62 (−54%), Quality Score 53/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AFP calculated?
We run Aft Pharmaceuticals Ltd through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of A$1.62 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Aft Pharmaceuticals Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aft Pharmaceuticals Ltd (AFP)?
The closing price on Nov 9, 2026 was A$3.55. Our model-based fair value is A$1.62, about 54% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aft Pharmaceuticals Ltd right now?
The price sits above even our optimistic bull case (A$3.09). The favourable scenario is already priced in. The model range is unusually wide (A$0.7700 to A$3.09). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Aft Pharmaceuticals Ltd
How large is the market capitalisation of Aft Pharmaceuticals Ltd (AFP)?
The market capitalisation of Aft Pharmaceuticals Ltd is A$372M (≈ $257M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Aft Pharmaceuticals Ltd (AFP)?
The price-to-sales ratio of Aft Pharmaceuticals Ltd is 1.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Aft Pharmaceuticals Ltd (AFP)?
Earnings per share at Aft Pharmaceuticals Ltd are A$0.1200 (price ÷ EPS = P/E 29.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Aft Pharmaceuticals Ltd (AFP)?
The dividend yield of Aft Pharmaceuticals Ltd is 0.7% (payout 20.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Aft Pharmaceuticals Ltd (AFP)?
The net margin of Aft Pharmaceuticals Ltd is 5.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Aft Pharmaceuticals Ltd (AFP)?
The return on equity (ROE) of Aft Pharmaceuticals Ltd is 13.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aft Pharmaceuticals Ltd (AFP)?
On an EBIT basis the return on assets of Aft Pharmaceuticals Ltd is 12.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aft Pharmaceuticals Ltd (AFP)?
The operating margin of Aft Pharmaceuticals Ltd is 14.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aft Pharmaceuticals Ltd (AFP)?
Revenue at Aft Pharmaceuticals Ltd is growing +15.2% versus a year earlier (3y avg +17.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Aft Pharmaceuticals Ltd (AFP)?
Earnings per share at Aft Pharmaceuticals Ltd are growing −16.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Aft Pharmaceuticals Ltd (AFP) generate?
The free cash flow of Aft Pharmaceuticals Ltd is −12.0M NZD (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Aft Pharmaceuticals Ltd (AFP) carry?
The net debt of Aft Pharmaceuticals Ltd is 44.2M NZD (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Aft Pharmaceuticals Ltd in the live analysis
One click puts Aft Pharmaceuticals Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026